CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Borgeson Blake Director | Sale 10b5-1 | −40,000 | $3.88 | $155K | 6,068,287 |
| 2026-11-02 | Hassan Fred Director | Grant or award | +156,658 | 156,658 | ||
| 2026-10-06 | Borgeson Blake Director | Sale 10b5-1 | −50,000 | $4.84 | $242K | 6,108,287 |
| 2026-10-06 | HERSHBERG ROBERT Director | Option exercise 10b5-1 | +25,000 | $2.22 | $56K | 187,156 |
| 2026-10-06 | HERSHBERG ROBERT Director | Sale 10b5-1 | −25,000 | $5.00 | $125K | 162,156 |
| 2026-10-06 | HERSHBERG ROBERT Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −25,000 | $2.22 | $56K | 500,000 |
| 2026-10-01 | Dar Zavain Director | Grant or award | +4,607 | 245,371 | ||
| 2026-10-01 | Li Dean Y Director | Grant or award | +3,378 | 1,476,707 | ||
| 2026-09-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −5,396 | $3.41 | $18K | 1,071,462 |
| 2026-09-08 | Khan Najat CEO and President | Sale 10b5-1 | −22,408 | $3.52 | $79K | 2,072,890 |
| 2026-09-01 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.34 | $100K | 6,158,287 |
| 2026-08-17 | Khan Najat CEO and President | Shares withheld for taxes | −80,498 | $3.16 | $254K | 2,095,298 |
| 2026-08-17 | Hallett David Chief Scientific Officer | Shares withheld for taxes | −26,657 | $3.16 | $84K | 1,043,837 |
| 2026-08-17 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −25,018 | $3.16 | $79K | 1,076,858 |
| 2026-08-04 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.25 | $98K | 6,188,287 |
| 2026-07-07 | Borgeson Blake Director | Sale 10b5-1 | −40,000 | $3.96 | $159K | 6,218,287 |
| 2026-07-01 | Dar Zavain Director | Grant or award | +5,109 | 240,764 | ||
| 2026-07-01 | Li Dean Y Director | Grant or award | +3,747 | 1,473,329 | ||
| 2026-06-18 | Bumpus Namandje Director | Sale 10b5-1 | −3,963 | $3.18 | $13K | 127,632 |
| 2026-06-17 | Borgeson Blake Director | Grant or award | +88,424 | 6,258,287 |
Page 1 of 9 · 179 trades